chronic severe pain
Pain · 2005–2019
11decisions
8medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the 5 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| oxycodone Chronic severe disabling pain unresponsive to non-opioid analgesics. The submission sought to restrict the non-crush-deterrent formulation (Oxycodone Sandoz)… | Jul 2019 | Noted | none received |
| buprenorphine Chronic severe disabling pain. The submission sought to list four additional patch strengths (15, 25, 30, 40 microgram/hour) to enable more appropriate dose… | Mar 2015 | Deferred | none received |
| oxycodone hydrochloride + naloxone hydrochloride Chronic severe disabling pain unresponsive to non-opioid analgesics. The naloxone component is indicated for therapy and/or prophylaxis of opioid-induced… | Mar 2015 | Deferred | none received |
| buprenorphine Chronic severe disabling pain unresponsive to non-narcotic analgesics. The submission sought listing of four additional patch strengths (15, 25, 30, and 40… | Nov 2015 | Recommended | no section in document |
| buprenorphine Chronic severe disabling pain in patients who have achieved a stable dose of buprenorphine patches. | Nov 2015 | Not recommended | none received |
| tapentadol Chronic severe disabling pain not responding to non-narcotic analgesics. | Mar 2012 | Not recommended | unclear |
| tapentadol Chronic severe disabling pain not responding to non-narcotic analgesics. | Mar 2011 | Not recommended | no section in document |
| oxycodone hydrochloride with naloxone hydrochloride dihydrate Chronic severe disabling pain not responding to non-narcotic analgesics. | Nov 2010 | Recommended with restriction | no section in document |
| fentanyl, transdermal patch chronic severe disabling pain not responding to non-narcotic analgesics | Mar 2006 | Recommended with restriction | no section in document |
| fentanyl Chronic severe disabling pain not responding to non-narcotic analgesics. The submission sought to extend PBS coverage beyond cancer pain to include non-cancer… | Mar 2006 | Recommended with restriction | no section in document |
| hydromorphone hydrochloride Chronic severe disabling pain not responding to non-narcotic analgesics. | Jul 2005 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.